ImPact Biotech
Biotechnology ResearchView the employees at
ImPact Biotech-
Zachary Sacks Head of Device Development at Steba biotech S.A
-
Israel
-
Top 10%
Sarit Samira Regulatory Affairs Specialist-
Israel
-
Top 5%
-
Tel Aviv-Yafo, Tel Aviv District, Israel
-
Top 5%
Keren Brook R&D Project Manager and Product Development-
Tel Aviv-Yafo, Tel Aviv District, Israel
-
Rising Star
Overview
ImPact Biotech is focused on the development and launch of Padeliporfin VTP (Vascular Targeted Photodynamic) therapy for the treatment of solid tumors. The company is headquartered in Israel, with presence in Luxembourg, France and USA, as well as its own GMP-certified (Good Manufacturing Practice) facility and research center in Israel. ImPact Biotech holds exclusive rights from the Weizmann Institute of Science (WIS, Israel) and Memorial Sloan Kettering Cancer Center (MSKCC, New York), to develop and commercialize drugs and related technologies used in VTP.
-